Table 1:
Socio-Demographic and Clinical Characteristics of Participants at Baseline
| Unweighted | Weighted* | ||||||
|---|---|---|---|---|---|---|---|
| Delayed | |||||||
| ART | Early ART | Delayed | Early ART | ||||
| Cohort | Cohort | P-value | ART Cohort | Cohort | P-value | ||
| Characteristics | N(%) | N(%) | N(%) | N(%) | |||
| Overall | 180(100%) | 176(100%) | 180(100%) | 176(100%) | |||
| Gender | |||||||
| Female | 96(53%) | 92(52%) | 0.841 | 88(49%) | 91(52%) | 0.584 | |
| Male | 84(47%) | 84(48%) | 92(51%) | 85(48%) | |||
| Age (years) | |||||||
| 18–24 | 21(12%) | 19(11%) | 0.272 | 22(12%) | 20(11%) | 0.418 | |
| 25–34 | 79(44%) | 90(51%) | 82(45%) | 88(50%) | |||
| 35–44 | 61(34%) | 44(25%) | 59(33%) | 46(26%) | |||
| 45–75 | 19(11%) | 23(13%) | 17(9%) | 23(13%) | |||
| CD4 counts (cells/µl) | |||||||
| 0–50 | 131(73%) | 133(76%) | 0.548 | 135(75%) | 131(74%) | 0.861 | |
| 51–100 | 49(27%) | 43(24%) | 45(25%) | 45(26%) | |||
| Haemoglobin (g/dL) | |||||||
| 0 – 8.0 | 59(33%) | 82(47%) | 0.008 | 76(42%) | 71(40%) | 0.677 | |
| 8.1 – 15.8 | 121(67%) | 94(53%) | 104(58%) | 105(60%) | |||
| WHO_Stage | |||||||
| III | 131(73%) | 89(51%) | <0.001 | 107(59%) | 108(61%) | 0.712 | |
| IV | 49(27%) | 87(49%) | 73(41%) | 68(39%) | |||
| Extra pulmonary TB | |||||||
| No | 137(76%) | 100(57%) | <0.001 | 115(64%) | 116(66%) | 0.680 | |
| Yes | 43(24%) | 76(43%) | 65(36%) | 60(34%) | |||
| CrAg Test result | |||||||
| Negative | 174(97%) | 155(88%) | 0.002 | 162(90%) | 162(92%) | 0.430 | |
| Positive | 6(3%) | 21(12%) | 18(10%) | 14(8%) | |||
*
Weighted using stabilized inverse probability weights
N=number, ART=antiretroviral therapy, WHO= World Health Organization, TB=tuberculosis, CrAg= cryptococcal antigen